Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 26 publications
Endocrine and multiple sclerosis outcomes in patients with autoimmune thyroid events in the alemtuzumab CARE-MS studies.
Journal: Multiple sclerosis journal - experimental, translational and clinical
Published: July 07, 2022
A Phase I, First-in-Human, Healthy Volunteer Study to Investigate the Safety, Tolerability, and Pharmacokinetics of CVN424, a Novel G Protein-Coupled Receptor 6 Inverse Agonist for Parkinson's Disease.
Journal: The Journal of pharmacology and experimental therapeutics
Published: July 13, 2021
Mismatch negativity as an index of target engagement for excitation/inhibition-based treatment development: a double-blind, placebo-controlled, randomized, single-dose cross-over study of the serotonin type-3 receptor antagonist CVN058.
Journal: Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology
Published: May 14, 2021
Efficacy and safety of alemtuzumab over 6 years: final results of the 4-year CARE-MS extension trial.
Journal: Therapeutic advances in neurological disorders
Published: July 23, 2020
Proportion of alemtuzumab-treated patients converting from relapsing-remitting multiple sclerosis to secondary progressive multiple sclerosis over 6 years.
Journal: Multiple sclerosis journal - experimental, translational and clinical
Published: April 20, 2020
Efficacy of alemtuzumab over 6 years in relapsing-remitting multiple sclerosis patients who relapsed between courses 1 and 2: Post hoc analysis of the CARE-MS studies.
Journal: Multiple sclerosis (Houndmills, Basingstoke, England)
Published: November 02, 2019
Impact of alemtuzumab on health-related quality of life over 6 years in CARE-MS II trial extension patients with relapsing-remitting multiple sclerosis.
Journal: Multiple sclerosis (Houndmills, Basingstoke, England)
Published: May 31, 2019
Incidence, management, and outcomes of autoimmune nephropathies following alemtuzumab treatment in patients with multiple sclerosis.
Journal: Multiple sclerosis (Houndmills, Basingstoke, England)
Published: April 16, 2019
Immune thrombocytopenia in alemtuzumab-treated MS patients: Incidence, detection, and management.
Journal: Multiple sclerosis (Houndmills, Basingstoke, England)
Published: February 21, 2019
Infection risk with alemtuzumab decreases over time: pooled analysis of 6-year data from the CAMMS223, CARE-MS I, and CARE-MS II studies and the CAMMS03409 extension study.
Journal: Multiple sclerosis (Houndmills, Basingstoke, England)
Published: October 06, 2018
Alemtuzumab improves quality-of-life outcomes compared with subcutaneous interferon beta-1a in patients with active relapsing-remitting multiple sclerosis.
Journal: Multiple sclerosis (Houndmills, Basingstoke, England)
Published: November 26, 2016
Last Updated: 09/26/2026